Aptose Biosciences (APTO) Director Carol Ashe Resigns – Form 8-K

Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.

Accepted by SEC EDGAR 06/18/2025 - 04:21 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.

The company states that Ms. Ashe’s departure was not related to any disagreement regarding operations, policies, or practices. Chairman, President & CEO William G. Rice, Ph.D. signed the filing on behalf of the board. No other management changes, financial data, or strategic transactions were reported.

Insights

Corporate Governance Expert

TL;DR: One director resigned; no disputes cited—governance change appears routine, minimal investor impact.

The 8-K solely reports Carol Ashe’s immediate resignation from Aptose’s board. Because the company affirms there were no disagreements, this event is typically viewed as an administrative governance update rather than a signal of operational stress or strategic shift. The filing contains no information on a replacement director or board composition implications, and there are no accompanying financial metrics or strategic announcements. For most investors, this represents a neutral, non-material event that does not alter the investment thesis or risk profile of APTO.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who resigned from the Aptose Biosciences (APTO) Board of Directors?

Director Carol Ashe submitted her resignation.

When did Carol Ashe’s resignation become effective?

Her resignation was effective June 16, 2025.

Did Carol Ashe cite any disagreements with Aptose Biosciences?

No. The Form 8-K states there were no disagreements regarding the company’s operations, policies, or practices.

When was the Form 8-K filed by Aptose Biosciences?

The report was filed on June 18, 2025.

Who signed the Form 8-K on behalf of Aptose Biosciences?

The filing was signed by William G. Rice, Ph.D., Chairman, President & CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0000882361 0000882361 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2025

APTOSE BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6

Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

On June 16, 2025, Carol Ashe notified the Board of Directors (the “Board”) of Aptose Biosciences Inc. (the “Company”) of her intention to resign from her role as a member of the Board effective immediately. Ms. Ashe’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. The Company thanks Ms. Ashe for her valuable contributions during her tenure as member of the Board and wishes her every success in her future endeavors.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: June 18, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer